CR20150320A - Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil) etil]-h-pirazol-3-il]-4-[(3r, 5s)-3,5-dimetilpiperazin-1-il]benzamida - Google Patents

Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil) etil]-h-pirazol-3-il]-4-[(3r, 5s)-3,5-dimetilpiperazin-1-il]benzamida

Info

Publication number
CR20150320A
CR20150320A CR20150320A CR20150320A CR20150320A CR 20150320 A CR20150320 A CR 20150320A CR 20150320 A CR20150320 A CR 20150320A CR 20150320 A CR20150320 A CR 20150320A CR 20150320 A CR20150320 A CR 20150320A
Authority
CR
Costa Rica
Prior art keywords
dimethylipiperazin
dimetoxifenil
benzamida
pirazol
etil
Prior art date
Application number
CR20150320A
Other languages
English (en)
Inventor
Noel Alan Weldon Baker
Alpesh Mistry
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49998566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR20150320A publication Critical patent/CR20150320A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Se proporcionan composiciones farmacéuticas que comprenden un compuesto de Fórmula (I), según se define en la presente, y una cantidad de un agente efervescente alcalino que sea suficiente para proporcionar una 5 disolución satisfactoria in vitro; y que comprenden además uno o más ingredientes farmacéuticamente aceptables; y procesos para obtenerlas.
CR20150320A 2012-12-21 2015-06-17 Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil) etil]-h-pirazol-3-il]-4-[(3r, 5s)-3,5-dimetilpiperazin-1-il]benzamida CR20150320A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740520P 2012-12-21 2012-12-21
PCT/GB2013/053356 WO2014096828A1 (en) 2012-12-21 2013-12-19 Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl] benzamide

Publications (1)

Publication Number Publication Date
CR20150320A true CR20150320A (es) 2015-09-11

Family

ID=49998566

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150320A CR20150320A (es) 2012-12-21 2015-06-17 Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil) etil]-h-pirazol-3-il]-4-[(3r, 5s)-3,5-dimetilpiperazin-1-il]benzamida

Country Status (26)

Country Link
US (2) US20140179712A1 (es)
EP (1) EP2934494B1 (es)
JP (1) JP6328138B2 (es)
KR (1) KR20150096787A (es)
CN (1) CN104853750B (es)
AR (1) AR094203A1 (es)
AU (1) AU2013366023B2 (es)
BR (1) BR112015014200A2 (es)
CA (1) CA2893480C (es)
CL (1) CL2015001786A1 (es)
CR (1) CR20150320A (es)
DO (1) DOP2015000127A (es)
ES (1) ES2742400T3 (es)
HK (1) HK1212229A1 (es)
IL (1) IL239521A0 (es)
MX (1) MX368670B (es)
NI (1) NI201500087A (es)
PE (1) PE20151418A1 (es)
PH (1) PH12015501389A1 (es)
RU (1) RU2674978C2 (es)
SG (1) SG11201504769WA (es)
TW (1) TWI651085B (es)
UA (1) UA115342C2 (es)
UY (1) UY35244A (es)
WO (1) WO2014096828A1 (es)
ZA (1) ZA201505197B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
WO2024031226A1 (zh) * 2022-08-08 2024-02-15 无锡和誉生物医药科技有限公司 Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB843940A (en) 1955-09-27 1960-08-10 Kodak Ltd Method of processing photographic silver halide emulsions containing colour couplers
BE667399A (es) 1964-07-30 1965-11-16
JPS57150846A (en) 1981-03-13 1982-09-17 Konishiroku Photo Ind Co Ltd Photographic element
JPS63133152A (ja) 1986-11-26 1988-06-04 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
JPH0467645A (ja) 1990-07-09 1992-03-03 Nec Kyushu Ltd バーンイン装置
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
JP2890065B2 (ja) 1990-11-10 1999-05-10 コニカ株式会社 ハロゲン化銀写真感光材料
JPH04184437A (ja) 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd カラー画像形成方法及びハロゲン化銀カラー写真感光材料
JPH04292322A (ja) 1991-03-19 1992-10-16 Fujitsu Ltd ラック給排装置
JPH0511414A (ja) 1991-07-02 1993-01-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
PL170837B1 (pl) 1991-10-18 1997-01-31 Monsanto Co S rod ek g r zybobó j c zy PL PL PL PL PL PL
BR9305466A (pt) 1992-03-26 1994-12-20 Dowelanco Nitroanilinas n-heterocíclicas usadas como fungicidas
HRP921338B1 (en) 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
TW240217B (es) 1992-12-30 1995-02-11 Glaxo Group Ltd
JP3156026B2 (ja) 1993-12-27 2001-04-16 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
WO1998028269A1 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP1012150A4 (en) 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
JP3310226B2 (ja) 1998-10-16 2002-08-05 松下電器産業株式会社 音声合成方法および装置
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CA2362381C (en) 1999-02-10 2009-12-22 Welfide Corporation Amide compounds and medicinal use thereof
AU3357700A (en) 1999-02-16 2000-09-04 E.I. Du Pont De Nemours And Company Phenoxypyrimidine insecticides and acaricides
YU9602A (sh) 1999-08-12 2004-11-25 Pharmacia Italia S.P.A. Derivati 3(5)-amino-pirazola, postupak za njihovu izradu i njihova upotreba kao antitumornih agenasa
PL366110A1 (en) 1999-08-13 2005-01-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1223944B1 (en) 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietin mimetics
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
US20040043904A1 (en) 2000-09-22 2004-03-04 Hiroshi Yamaguchi N-(4-pyrazolyl) amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
ATE553758T1 (de) 2000-12-18 2012-05-15 Inst Med Molecular Design Inc Hemmer für die produktion und freisetzung entzündlicher zytokine
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CA2445357A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
CN101103977A (zh) 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
TW200407112A (en) 2002-06-05 2004-05-16 Inst Med Molecular Design Inc Immunity-related protein kinase inhibitors
WO2003103665A1 (ja) 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
WO2004013137A1 (en) 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
WO2004098528A2 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7115359B2 (en) 2003-07-25 2006-10-03 Konica Minolta Medical & Graphic, Inc. Photothermographic material
AU2004268948A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
US7432271B2 (en) 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
US7767670B2 (en) 2003-11-13 2010-08-03 Ambit Biosciences Corporation Substituted 3-carboxamido isoxazoles as kinase modulators
ATE473967T1 (de) 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US7531556B2 (en) 2004-04-28 2009-05-12 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
KR20080031997A (ko) 2005-08-02 2008-04-11 아이알엠 엘엘씨 단백질 키나제 억제제로서의 5-치환 티아졸-2-일 아미노화합물 및 조성물
EP1945190A1 (en) * 2005-09-22 2008-07-23 Swissco Devcelopment AG Effervescent metformin composition and tablets and granules made therefrom
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
WO2010121323A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
WO2010137855A2 (en) * 2009-05-27 2010-12-02 Dasan Medichem Co., Ltd. Multi-layer tablet comprising effervescent layer
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Also Published As

Publication number Publication date
CA2893480C (en) 2021-01-12
NI201500087A (es) 2016-02-16
ES2742400T3 (es) 2020-02-14
PH12015501389A1 (en) 2015-09-02
PE20151418A1 (es) 2015-10-21
EP2934494A1 (en) 2015-10-28
WO2014096828A1 (en) 2014-06-26
US20170119759A1 (en) 2017-05-04
AU2013366023B2 (en) 2016-10-27
CN104853750A (zh) 2015-08-19
HK1212229A1 (en) 2016-06-10
US20140179712A1 (en) 2014-06-26
MX2015008067A (es) 2016-04-25
TWI651085B (zh) 2019-02-21
CL2015001786A1 (es) 2015-08-14
ZA201505197B (en) 2017-07-26
AU2013366023A1 (en) 2015-06-18
CA2893480A1 (en) 2014-06-26
CN104853750B (zh) 2018-06-26
MX368670B (es) 2019-10-10
BR112015014200A2 (pt) 2017-07-11
JP2016503782A (ja) 2016-02-08
RU2015126345A (ru) 2017-01-30
SG11201504769WA (en) 2015-07-30
US10420764B2 (en) 2019-09-24
AR094203A1 (es) 2015-07-15
UA115342C2 (uk) 2017-10-25
EP2934494B1 (en) 2019-06-12
TW201431553A (zh) 2014-08-16
DOP2015000127A (es) 2015-07-31
RU2674978C2 (ru) 2018-12-14
KR20150096787A (ko) 2015-08-25
JP6328138B2 (ja) 2018-05-23
IL239521A0 (en) 2015-08-31
UY35244A (es) 2014-01-31

Similar Documents

Publication Publication Date Title
AR117001A2 (es) Formulación de premezcla de dexmedetomidina
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
CR20210108A (es) Benzamidas sustituidas con 1, 3-tiazol-2-ilo
MX2013014846A (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos.
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
PH12015502542A1 (en) Stabilized pemetrexed formulation
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PE20140255A1 (es) Tableta dispersable en forma oral
BR112014016550A8 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112013019394A2 (pt) uso de um agente
MY163476A (en) Oral care compositions
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
EA201490573A1 (ru) Соединение бензотиазолона
TR201901792T4 (tr) Yeni (trimetoksifenilamino)pirimidinil formülasyonları.
CR20150320A (es) Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil) etil]-h-pirazol-3-il]-4-[(3r, 5s)-3,5-dimetilpiperazin-1-il]benzamida
RU2013110517A (ru) Средство для профилактики или лечения неалкогольного стеатогепатита
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
IN2013MU02442A (es)
RS54022B1 (en) COMPOSITION OF VIRUS INHIBITOR FOR INVIVE THERAPEUTIC USE
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування